-
Gland Pharma Share Price Jumps to a 52-Week High Despite the Market Sell-Off: Q2 FY27 Profit, CDMO Growth and What to Check
- November 9, 2026
- Posted by: Chaitanya Auti
- Category: News
No Comments
Gland Pharma share price jumped 7% to a 52-week high after Q2 FY27 profit rose 58% to Rs 290.8 crore. Results, CEO change, valuation and checks.
-
3 Contract Development Company, Pain and Chronic Care Brand Owner and Active Ingredients Maker Stocks With a Strong Future Roadmap: Anthem Biosciences, Ipca Laboratories and Granules India
- October 28, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Development, Pain Brand and API Pharma with a strong future roadmap: Anthem Biosciences, Ipca Laboratories and Granules India. Compare price, valuation, return on equity and revenue growth as of 27 October 2026.
-
3 Research-Driven Contract Manufacturer, Over-the-Counter Formulations Exporter and Point-of-Care Molecular Diagnostics Maker Stocks With a Strong Future Roadmap: Anthem Biosciences, Marksans Pharma and Molbio Diagnostics
- October 26, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
CDMO, OTC Pharma and Diagnostics Stocks with a strong future roadmap: Anthem Biosciences, Marksans Pharma and Molbio Diagnostics. Compare price, valuation, return on equity and revenue growth as of 23 October 2026.
-
This Contract Manufacturing Pharma Stock Rises 33% in 1 Year: What Changed at the Jammu Plant
- September 18, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
One Baddi-based formulations maker gained about 33% in twelve months, almost all of it after March 2026. Here is what changed at its newest plant, and what still worries the market.